Ishita Pharmaceuticals, a related party of ishita drugs & indus , has acquired 55 shares of ₹10 each in the company through an open market transaction. The acquisition, disclosed to BSE Limited on June 19, 2026, was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This transaction increases the acquirer's stake in the pharmaceutical manufacturer, though the overall percentage holding remains unchanged at 1.09%.

Acquisition Details

The disclosure confirms that Ishita Pharmaceuticals purchased 55 equity shares carrying voting rights. Prior to this acquisition, the acquirer held 32,642 shares, accounting for 1.09% of the total share capital and voting rights. The latest purchase brings the total holding to 32,697 shares. The equity share capital of Ishita Drugs and Industries Limited remains at ₹29,903,000, comprising 2,990,300 shares of ₹10 each.

Holding Structure

The filing details the acquirer's position before and after the transaction. There were no changes in encumbrances, voting rights held otherwise than by shares, or holdings in warrants and convertible securities. The entire acquisition consisted of shares carrying voting rights.

Regulatory Filing

The disclosure was submitted to BSE Limited, where Ishita Drugs and Industries Limited is listed under scrip code 524400. Ishita Pharmaceuticals is classified as a related party of the target company rather than a member of the promoter or promoter group. The transaction was executed on June 19, 2026, and the necessary disclosures were filed on the same date to comply with SEBI regulations.

Ishita Drugs & Industries Limited reported a net profit of ₹77.85 lakh for the financial year ended March 31, 2026, a decrease from ₹86.81 lakh in the previous year. The company's board approved the audited financial results for the quarter and year ended March 31, 2026, during a meeting held on May 30, 2026. Revenue from operations for the year stood at ₹1466.02 lakh, compared to ₹1499.73 lakh in FY25. For the quarter ended March 31, 2026, the company recorded a net profit of ₹17.74 lakh on revenue of ₹305.54 lakh.

Financial Performance

The total income for FY26 was ₹1513.34 lakh, lower than ₹1533.30 lakh in the previous year. Total expenses for the year were ₹1405.34 lakh, a reduction from ₹1417.78 lakh in FY25. The company reported a basic earnings per share (EPS) of ₹2.60 for FY26, down from ₹2.90 in the preceding year. For the quarter ended March 31, 2026, the EPS was ₹0.59.

Balance Sheet Highlights

The company's total assets as of March 31, 2026, were ₹1260.37 lakh, a decrease from ₹1629.59 lakh in the previous year. Total equity stood at ₹1156.81 lakh, up from ₹1078.96 lakh. Current assets decreased to ₹954.22 lakh from ₹1498.35 lakh, while current liabilities reduced significantly to ₹98.85 lakh from ₹540.48 lakh.

Cash Flow Statement

Net cash generated from operating activities for FY26 was ₹391.93 lakh, a positive shift from the negative ₹363.71 lakh reported in the previous year. However, the company saw a net decrease in cash and cash equivalents of ₹212.98 lakh, bringing the closing balance to ₹270.40 lakh.

Auditor's Report

Jaymin Shah & Associates, Chartered Accountants, issued an unmodified opinion on the standalone financial results. The report confirms that the results give a true and fair view of the company's financial position in conformity with Indian accounting standards. The trading window for designated persons remains closed until 48 hours after the announcement of these results.